Monday, November 17, 2025
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat
GeneDx Holdings Corp. (NASDAQ:WGS) is one...
Tempus AI Retains Buy Rating as Canaccord Adjusts Price Target to $95 After Q3 Beat
Tempus AI, Inc. (NASDAQ:TEM) is one...
Veeva Expands Basics Suite as Over 100 Biotechs Adopt Platform for Scalable Growth
Veeva Systems Inc. (NYSE:VEEV) is one...
“CFD Brokers Don’t Really Understand Risk Management”: ‘Rogue Trader’ Nick Leeson
“CFD brokers don’t really understand risk management or the...
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat
GeneDx Holdings Corp. (NASDAQ:WGS) is one...
Tempus AI Retains Buy Rating as Canaccord Adjusts Price Target to $95 After Q3 Beat
Tempus AI, Inc. (NASDAQ:TEM) is one...
Veeva Expands Basics Suite as Over 100 Biotechs Adopt Platform for Scalable Growth
Veeva Systems Inc. (NYSE:VEEV) is one...
“CFD Brokers Don’t Really Understand Risk Management”: ‘Rogue Trader’ Nick Leeson
“CFD brokers don’t really understand risk management or the...
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat
GeneDx Holdings Corp. (NASDAQ:WGS) is one...
Tempus AI Retains Buy Rating as Canaccord Adjusts Price Target to $95 After Q3 Beat
Tempus AI, Inc. (NASDAQ:TEM) is one...
Veeva Expands Basics Suite as Over 100 Biotechs Adopt Platform for Scalable Growth
Veeva Systems Inc. (NYSE:VEEV) is one...
“CFD Brokers Don’t Really Understand Risk Management”: ‘Rogue Trader’ Nick Leeson
“CFD brokers don’t really understand risk management or the...
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat
GeneDx Holdings Corp. (NASDAQ:WGS) is one...
Tempus AI Retains Buy Rating as Canaccord Adjusts Price Target to $95 After Q3 Beat
Tempus AI, Inc. (NASDAQ:TEM) is one...
Veeva Expands Basics Suite as Over 100 Biotechs Adopt Platform for Scalable Growth
Veeva Systems Inc. (NYSE:VEEV) is one...
“CFD Brokers Don’t Really Understand Risk Management”: ‘Rogue Trader’ Nick Leeson
“CFD brokers don’t really understand risk management or the...
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat
GeneDx Holdings Corp. (NASDAQ:WGS) is one...
Tempus AI Retains Buy Rating as Canaccord Adjusts Price Target to $95 After Q3 Beat
Tempus AI, Inc. (NASDAQ:TEM) is one...
Veeva Expands Basics Suite as Over 100 Biotechs Adopt Platform for Scalable Growth
Veeva Systems Inc. (NYSE:VEEV) is one...
“CFD Brokers Don’t Really Understand Risk Management”: ‘Rogue Trader’ Nick Leeson
“CFD brokers don’t really understand risk management or the...
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat
GeneDx Holdings Corp. (NASDAQ:WGS) is one...
Tempus AI Retains Buy Rating as Canaccord Adjusts Price Target to $95 After Q3 Beat
Tempus AI, Inc. (NASDAQ:TEM) is one...
Veeva Expands Basics Suite as Over 100 Biotechs Adopt Platform for Scalable Growth
Veeva Systems Inc. (NYSE:VEEV) is one...
“CFD Brokers Don’t Really Understand Risk Management”: ‘Rogue Trader’ Nick Leeson
“CFD brokers don’t really understand risk management or the...
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat
GeneDx Holdings Corp. (NASDAQ:WGS) is one...
Tempus AI Retains Buy Rating as Canaccord Adjusts Price Target to $95 After Q3 Beat
Tempus AI, Inc. (NASDAQ:TEM) is one...
Veeva Expands Basics Suite as Over 100 Biotechs Adopt Platform for Scalable Growth
Veeva Systems Inc. (NYSE:VEEV) is one...
“CFD Brokers Don’t Really Understand Risk Management”: ‘Rogue Trader’ Nick Leeson
“CFD brokers don’t really understand risk management or the...
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat
GeneDx Holdings Corp. (NASDAQ:WGS) is one...
Tempus AI Retains Buy Rating as Canaccord Adjusts Price Target to $95 After Q3 Beat
Tempus AI, Inc. (NASDAQ:TEM) is one...
Veeva Expands Basics Suite as Over 100 Biotechs Adopt Platform for Scalable Growth
Veeva Systems Inc. (NYSE:VEEV) is one...
“CFD Brokers Don’t Really Understand Risk Management”: ‘Rogue Trader’ Nick Leeson
“CFD brokers don’t really understand risk management or the...
Free News - Where voices unite, stories flourish, and community thrives through open dialogue and meaningful connections.
Headlines
Guggenheim Reaffirmed Buy on GeneDx at October End, Lifted Price Target to $170 After Q3 Beat
GeneDx Holdings Corp. (NASDAQ:WGS) is one...
Tempus AI Retains Buy Rating as Canaccord Adjusts Price Target to $95 After Q3 Beat
Tempus AI, Inc. (NASDAQ:TEM) is one...
Veeva Expands Basics Suite as Over 100 Biotechs Adopt Platform for Scalable Growth
Veeva Systems Inc. (NYSE:VEEV) is one...
Newsletter
Get important news delivered directly to your inbox and stay connected!